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Combination Therapies Including Guadecitabine in 
E0771 Murine Triple-Negative Breast Cancer Model
Jamie-Jean S. Gilmer1, Laura J. Graham2,4, Harry D. Bear2,3,4
Conclusions
Ø Guadecitabine alone and in combination with 
trametinib increases PD-L1 and MHC class I 
expression and inhibits cell proliferation in vitro
Ø Early treatment with guadecitabine significantly 
suppresses initial tumor growth in vivo
Ø Guadecitabine combined with AIT is highly effective 
at suppressing tumor growth and produces a high 
cure rate
Ø Treatment with guadecitabine combined with 
paclitaxel and anti-PD-1/L1 
Ø Paclitaxel may not be the best partner for 
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Ø Cancer is the second leading cause of death in the 
U.S. Triple-negative breast cancer (TNBC) is 
associated with poor prognosis due to lack of 
estrogen receptor (ER-), progesterone receptor (PR-), 
and amplified human epidermal growth factor 
receptor 2 (HER2-), so other targets are needed.
Ø Dysregulation of the MEK pathway is a mechanism 
commonly involved in the proliferation and immune 
evasion of malignant cells, including TNBC. 
Trametinib is a MEK1/2 inhibitor that may inhibit 
tumor growth.
Ø One of the hallmarks of cancer is avoiding immune 
destruction. Various mechanisms used for immune 
evasion include upregulation of immune checkpoint 
molecules (like PD-1/L1), hypermethylation of tumor 
suppressors, induction of immune-suppressive cells, 
downregulation of MHC class I, and immunoediting. 
These mechanisms can be inhibited using a DNA 
methyl-transferase inhibitor (DMTi)
Ø Guadecitabine is a next-generation DMTi that is more 
stable and lasts longer in circulation than its parent 
molecule, decitabine. Guadecitabine has been found 
to augment anti-tumor T cell activity in adoptive 
immunotherapy (AIT) in other murine TNBC models.
Ø Recently, a regimen of Taxol (paclitaxel) and 
Atezolizumab (anti-PD-L1) was approved for clinical 
trials treating metastatic TNBC. Guadecitabine may 
improve the efficacy of this regimen. 
Background Methods
Ø All mice were inoculated with 200 thousand E0771 
cells suspended in PBS (1X) via subcutaneous 
injection to establish tumors on the left flank. Tumor 
volumes were measured twice per week (every 3 or 4 
days) starting post-inoculation day 7 along two axes 
(length and width) and tumor volumes were 
calculated as (length/2)(width2).
Ø E0771 cells were maintained in complete Roswell 
Park Memorial Institute (RPMI) cell medium plus 10% 
fetal bovine serum (FBS), 0.075% sodium 
bicarbonate, 1mM sodium pyruvate, 0.1mM non-
essential amino acids (NMEM) (1X), 100 units/mL 
penicillin, 100μg/mL streptomycin, 10mM hepes, 
5x10-5 M 2-mercaptoethanol, and 2mM L-glutamine. 
The cells were harvested using 0.05% trypsin-EDTA.
Results
E0771 (200k) tumors in C57Bl/6 mice treated with 
guadecitabine (50ug days 3-6)
and/or anti-PD-1 (100ug days 4,7,10,13)
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E0771 tumors (200k) in C57Bl/6 mice
treated with paclitaxel (5mg/kg, day 7),
 guadecitabine (50ug, days 9-11), 
and anti-PD-1 (100ug, days 10,13,17,20)
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E0771 tumors (200k) in C57Bl/6 mice
treated with paclitaxel (5mg/kg, day 7),
 guadecitabine (50ug, days 9-11), 
and anti-PD-L1 (100ug, days 10,13,17,20)
Days of Growth
0 20 40 60 80 100
Tu
mo
r V
olu
me
 (m
m^
3)
0
100
200
300
400
500
600
Days vs Control 
Days vs pac 
Days vs gua+pac 
Days vs pac+anti-PD-L1 
Days vs gua+pac+anti-PD-L1 
*0/5
*0/5*0/5
*0/5
*0/5
Future Directions
Ø Repeat studies in 4T1 murine TNBC model
Ø Studies of cell populations in solid tumor, tumor 
microenvironment, and lymphatic organs after 
treatment
Ø Guadecitabine, paclitaxel, and anti-PD-1/L1 with AIT
Ø Guadecitabine and Adriamycin and anti-PD-1/L1
